Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: COOPERATIVE MULTICENTER TRIAL FOR THE TREATMENT OF INFANTS WITH NEUROBLASTOMA
Brief Summary: RATIONALE: Sometimes neuroblastoma will regress without treatment, but sometimes additional treatment may be necessary. Giving more than one chemotherapy drug after surgery to remove the tumor may kill more tumor cells.

PURPOSE: Phase II trial to study combination chemotherapy or observation following surgery in treating infants with neuroblastoma.


Options:
A: Arm Label: R0: COJEC plus G-CSF; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: G-CSF | Arm Label: R0: COJEC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R1: BuMel MAT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Busulfan, Drug: Melphalan | Arm Label: R1: CEM MAT; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Melphalan | Arm Label: R2: ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R2: ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Arm Label: R3: COJEC Induction; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R3: Modified N7; Type: EXPERIMENTAL; Interventions: Drug: Vincristine, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Doxorubicin | Arm Label: R4: cnt inf ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R4: cnt inf ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): R0: COJEC, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: ch14.18/CHO; Assigned to Arm(s): R2: ch14.18/CHO, R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): R3: Modified N7 | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): R0: COJEC plus G-CSF | Intervention Type: DRUG; Name: Busulfan; Assigned to Arm(s): R1: BuMel MAT | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): R1: BuMel MAT, R1: CEM MAT
B: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tretinoin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A

Answer: D